In vitro evaluation of the effect of temporary removal of HIV drug pressure. (Q55239961)

28 June 2018

title

In vitro evaluation of the effect of temporary removal of HIV drug pressure. (English)

1 reference

28 June 2018

author

Christophe Pannecouque

2

1 reference

28 June 2018

Erik De Clercq

4

1 reference

28 June 2018

author name string

Witvrouw M

1

1 reference

28 June 2018

Desmyter J

3

1 reference

28 June 2018

Andries K

5

1 reference

28 June 2018

publication date

1 June 2000

1 reference

28 June 2018

published in

Antiviral Research

1 reference

28 June 2018

volume

46

1 reference

28 June 2018

issue

3

1 reference

28 June 2018

page(s)

215-221

1 reference

28 June 2018

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Combination therapy for infection due to human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. The Belgian AIDS Reference Laboratories.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

10.1016/S0166-3542(00)00084-X

Identifiers

DOI

1 reference

28 June 2018

1 reference

28 June 2018